3. SMART Medical Review: CA 19-9 and pancreatic ductal adenocarcinoma (PDAC).
CA 19-9 and Pancreatic Cancer
DOI:
https://doi.org/10.69734/psc3br75Abstract
Carbohydrate antigen 19-9 (CA 19-9) is the sole FDA-approved serum biomarker for early detection, progression, and treatment response of pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer). It is more specific than other serum biomarkers for PDAC. Understanding the clinical relevance of genetic variants and other conditions on CA 19-9 expression is thus critical for proper interpretation. This review covers PDAC risk assessment, screening, early diagnosis and treatment monitoring with a focus on CA 19-9 and genetic factors that influence serum levels with or without PDAC.
References
Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19(2):182-6. PMID: 14731128
Bennett C, Suguitan M, Abad J, Chawla A. Identification of high-risk germline variants for the development of pancreatic cancer: Common characteristics and potential guidance to screening guidelines. Pancreatology. 2022;22(6):719-29. PMID: 35798629
Zhan W, Shelton CA, Greer PJ, Brand RE, Whitcomb DC. Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts. Pancreas. 2018;47(8):924-36. PMID: 30113427
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17. PMID: 31672839
Sharma S, Tapper WJ, Collins A, Hamady ZZR. Predicting Pancreatic Cancer in the UK Biobank Cohort Using Polygenic Risk Scores and Diabetes Mellitus. Gastroenterology. 2022;162(6):1665-74 e2. PMID: 35065983
Kachuri L, Graff RE, Smith-Byrne K, Meyers TJ, Rashkin SR, Ziv E, et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nature communications. 2020;11(1):6084. PMID: 33247094
Wang L, Grimshaw AA, Mezzacappa C, Rahimi Larki N, Yang YX, Justice AC. Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37610426
Kim J, Yuan C, Babic A, Bao Y, Clish CB, Pollak MN, et al. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiol Biomarkers Prev. 2020;29(5):999-1008. PMID: 32321713
Dite GS, Spaeth E, Wong CK, Murphy NM, Allman R. Predicting 10-Year Risk of Pancreatic Cancer Using a Combined Genetic and Clinical Model. Gastro Hep Advances. 2023;2(7):P979-89. PMID:
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186-98. PMID: 25502106
Whitcomb DC, Shelton C, Brand RE. Genetics and Genetic Testing in Pancreatic Cancer. Gastroenterology. 2015;149(5):1252-64. PMID: 26255042
Wolpin BM, Kraft P, Xu M, Steplowski E, Olsson ML, Arslan AA, et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3140-9. PMID: 20971884
Morani AC, Hanafy AK, Ramani NS, Katabathina VS, Yedururi S, Dasyam AK, et al. Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging. Radiol Imaging Cancer. 2020;2(2):e190020. PMID: 33778702
Tan M, Brusgaard K, Gerdes AM, Mortensen MB, Detlefsen S, Schaffalitzky de Muckadell OB, et al. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study. Scand J Gastroenterol. 2021:1-7. PMID: 34165379
Porter N, Laheru D, Lau B, He J, Zheng L, Narang A, et al. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. J Natl Cancer Inst. 2022;114(12):1681-8. PMID: 36029239
Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters MLB, et al. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer. 2018;124(17):3520-7. PMID: 30067863
Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. JAMA Oncol. 2020;6(5):764-71. PMID: 32053139
Bogumil D, Conti DV, Sheng X, Xia L, Shu XO, Pandol SJ, et al. Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2686-92. PMID: 32958499
Satake K, Takeuchi T, Homma T, Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas. 1994;9(6):703-6. PMID: 7846012
Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepato-gastroenterology. 2006;53(67):1-4. PMID: 16506366
Whitcomb DC. Primer on Precision Medicine for Complex Chronic Disorders. Clin Transl Gastroenterol. 2019;10(7):e00067. PMID: 31335357
Atkinson AJJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. PMID: 11240971
Whitcomb DC. Better Biomarkers for Pancreatic Diseases. Pancreas. 2015;44(8):1171-3. PMID: 26465944
Hanna-Sawires RG, Schiphuis JH, Wuhrer M, Vasen HFA, van Leerdam ME, Bonsing BA, et al. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. Int J Mol Sci. 2021;22(5). PMID: 33800786
Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159(1):358-62. PMID: 32416142
Kato S, Honda K. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers (Basel). 2020;12(7). PMID: 32707720
Sasaki A, Sakata K, Nakano K, Tsutsumi S, Fujishima H, Futsukaichi T, et al. DUPAN-2 as a Risk Factor of Early Recurrence After Curative Pancreatectomy for Patients With Pancreatic Ductal Adenocarcinoma. Pancreas. 2023;52(2):e110-e4. PMID: 37523601
Takagi T, Nagai M, Nishiwada S, Terai T, Yasuda S, Matsuo Y, et al. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2023;7(2):326-35. PMID: 36998299
Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K, et al. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg. 2017;265(4):800-5. PMID: 28267695
Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, et al. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2020;18(5):1161-9 e5. PMID: 31676359
Guo M, Luo G, Lu R, Shi W, Cheng H, Lu Y, et al. Distribution of Lewis and Secretor polymorphisms and corresponding CA19-9 antigen expression in a Chinese population. FEBS Open Bio. 2017;7(11):1660-71. PMID: 29123975
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, et al. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology. 2016;16(6):1057-62. PMID: 27692554
Scara S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:247-60. PMID: 26530370
Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int. 2009;8(6):620-6. PMID: 20007080
Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol. 2015;21(14):4323-33. PMID: 25892884
Jiang Q, Lei L, Zhang X, Pressley J, Mao Y. The Correlated Factors of Serum CA19-9 Levels in Diabetic Patients. Curr Diabetes Rev. 2017;13(1):47-9. PMID: 26456360
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 1998;35 ( Pt 1):99-103. PMID: 9463746
Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia. 2003;58(5):667-72. PMID: 15190651
Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases. Intern Med. 1999;38(11):840-1. PMID: 10563741
Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, et al. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer. 2018;118(12):1609-16. PMID: 29872151
Wannhoff A, Folseraas T, Brune M, Rupp C, Friedrich K, Knierim J, et al. A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European gastroenterology journal. 2016;4(1):84-91. PMID: 26966527
Soejima M, Koda Y. Simultaneous genotyping of three major Se enzyme inactivating SNPs of FUT2 based on a triplex probe-based fluorescence melting-curve analysis. Clin Chim Acta. 2022;530:50-4. PMID: 35271838
Zhernakova DV, Le TH, Kurilshikov A, Atanasovska B, Bonder MJ, Sanna S, et al. Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome. Nat Genet. 2018;50(11):1524-32. PMID: 30250126
Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem. 1995;270(9):4640-9. PMID: 7876235
Orntoft TF, Vestergaard EM, Holmes E, Jakobsen JS, Grunnet N, Mortensen M, et al. Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. J Biol Chem. 1996;271(50):32260-8. PMID: 8943285
Elmgren A, Mollicone R, Costache M, Borjeson C, Oriol R, Harrington J, et al. Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1,3/1,4)-fucosyltransferase, Fuc-TIII. J Biol Chem. 1997;272(35):21994-8. PMID: 9268337
Brand RE, Persson J, Bratlie SO, Chung DC, Katona BW, Carrato A, et al. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Clin Transl Gastroenterol. 2022;13(3):e00468. PMID: 35166713
Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(7):11683-91. PMID: 26380005
Molina-Montes E, Gomez-Rubio P, Marquez M, Rava M, Lohr M, Michalski CW, et al. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Int J Epidemiol. 2018;47(2):473-83. PMID: 29329392
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-502. PMID: 34002083
Gonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, et al. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointest Endosc. 2022;95(4):723-32 e7. PMID: 34736932
Singhi AD, Nikiforova MN, Chennat J, Papachristou GI, Khalid A, Rabinovitz M, et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut. 2020;69(1):52-61. PMID: 30971436
Nikiforova MN, Wald AI, Spagnolo DM, Melan MA, Grupillo M, Lai YT, et al. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising from Pancreatic Cysts. Ann Surg. 2023. PMID: 37212422
Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, et al. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171. PMID: 24890327
Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20(7):2188-96. PMID: 23247983
Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897-902. PMID: 16782929
Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017;87(12):987-92. PMID: 28803454
Liu H, Zenati MS, Rieser CJ, Al-Abbas A, Lee KK, Singhi AD, et al. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Ann Surg Oncol. 2020;27(10):3950-60. PMID: 32318949
Published
Issue
Section
License
Copyright (c) 2024 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information